Molecular Formula	Fe3O4
Molecular Weight	231.53
Structure
State	solid
Clearance	Since there is no renal clearance, ferumoxytol is safe in renal failure patients [L2184]. One study estimated the clearance to be **0.0221 L/h** [L2179].
Volume of distribution	The population mean estimates for volume of distribution of the central compartment (V(1)), maximum elimination rate (V(max)), and ferumoxytol concentration at which rate of metabolism would be one-half of V(max) (K(m)) were 2.71 l, 14.3 mg/hr, and 77.5 mg/L, respectively [L2182].
Route of elimination	Iron can either become a component of intracellular ferritin or be transferred to erythroid precursor cells [L2185].
Half life	The pharmacokinetic (PK) behavior of Feraheme has been studied in healthy subjects and in patients with stage 5D of chronic kidney disease, on hemodialysis [L2182]. Feraheme showed dose-dependent, capacity-limited elimination from the plasma with a half-life of **approximately 15 hours** in humans [L2182].
Absorption	Bioavailability studies were not conducted as ferumoxytol has been developed for IV administration only [L2179]. Iron therapy dosage is individualized according to specific goals for blood iron concentrations, iron storage parameters (e.g., ferritin, transferrin saturation), and serum hemoglobin concentrations. Iron toxicity is possible with excessive or unnecessary iron therapy. Systemic iron is stored in ferritin and hemosiderin, which are utilized for future production of hemoglobin. The absorption of iron depends on the route of administration. The tissue that first clears parenterally ingested iron from the plasma determines its bioavailability. If the reticuloendothelial system clears iron effectively, only small amounts will become available over time to the bone marrow. Transferrin accepts iron from the intestinal tract and also from sites of hemoglobin storage and destruction [L2190].

Iron deficiency

Iron deficiency anaemia

Renal failure chronic

Constipation (0.00021)

Diarrhoea (4e-04)

Hypertension (1e-04)

Abdominal pain

Back pain

Body temperature increased

Chest pain

Cough

Dermatitis

Dizziness

Dyspnoea

Gastrointestinal pain

Headache

Hypotension

Muscle spasms

Nausea

Oedema

Oedema peripheral

Pruritus

Rash

Vomiting

120899-48-1	12227-89-3	DB06215
Fe3O4	IRON PIGMENT BLACK (E172)	Iron (II,III) oxide
Iron Oxide Black	Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL Fe in H2O, dispersion	Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), carboxylic acid functionalized, 5 mg/mL Fe in H2O, dispersion	Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in H2O	Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in toluene
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm diameter, biotin functionalized, 1 mg/mL Fe, dispersion in H2O	Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in H2O	Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in toluene
Iron oxide(II,III), magnetic nanoparticles solution, 30 nm avg. part. size (TEM), PEG functionalized, dispersion, 1 mg/mL Fe in H2O	Iron oxide(II,III), magnetic nanoparticles solution, 30 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion	Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL Fe in H2O, dispersion
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion	Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), biotin functionalized, 1 mg/mL Fe in H2O, dispersion	Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in H2O
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in toluene	Iron(II,III) oxide, 99.99% trace metals basis	Iron(II,III) oxide, CP
Iron(II,III) oxide, nanopowder, 50-100 nm particle size (SEM), 97% trace metals basis	Iron(II,III) oxide, powder, <5 mum, 95%	Iron(II,III)oxide
Q411235	S350	SZVJSHCCFOBDDC-UHFFFAOYSA-N

DrugBank Name	Ferumoxytol
DrugBank	DB06215
CAS Number	120899-48-1, 12227-89-3, 1317-61-9
PubChem Compound	16211978
KEGG Compound ID	x
KEGG Drug	D04177
PubChem.Substance	347827764
ChEBI	50821
ChemSpider	4937312
Wikipedia	Iron(II,III)_oxide
DPD	309